Implantica
Business Services · Switzerland · 64 Employees
View Company Info for Free
About
Headquarters
57 Baarerstrasse, Zug, Zug, 6300, SwitzerlandPhone Number
+41 415391908Website
www.implantica.comRevenue
<$5 MillionIndustry
Who is Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop, is a CE-marked implan t for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).Read more
Implantica Org Chart
Is Implantica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Implantica recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Implantica has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Implantica has recently received funding, and reach out quickly before it becomes old news!
Click to see if Implantica had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Implantica
Product Launch: Get notified when Implantica launches new products
Check out if Implantica is spiking on competitors!
Implantica, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Implantica Employee Growth Rate
View Implantica’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Implantica Tech Stack
A closer look at the technologies used by Implantica
See more technologies
Most Recent Scoops
Last Week
Hot Scoop - Business
Last month
Hot Scoop - Financial
Last month
Hot Scoop - Opportunities
Implantica News & Media
Implantica announces excellent data from an independent study of 158 RefluxStop™ patients from two centers in Germany – presented at the AUGIS meeting in UK
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, reports that the study “Pooled two-year results of the novel RefluxStop implantable device in management of gastroesophageal reflux disease in Germany: Retrospective analysis,” shows over 90% improvement in GERD quality-of-life scores in patients 2 years after the procedure. The study was recently presented at the Association of Upper Gastrointestinal Surgery of Great Britain and Ireland (
Implantica mourns the death of board member Prof. Dr. Klaus Neftel
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces with regret that Prof. Dr. Klaus Neftel, a member of the Implantica Board of Directors, has passed away. Prof. Dr. Neftel was appointed as a director of the Implantica Group in January 2018. He was the former Chief of Internal Medicine at the Ziegler Hospital in Bern as well as a Professor at the University of Bern. HeImplantica publishes Interim Report January – June 2024 (Q2)
RefluxStop™ is on a wave of success – carried by a multitude of published studies with excellent outcomes from leading European Reflux-centers Significant events in the second quarter of 2024 · Module 1 review of Premarket Approval (PMA) application for RefluxStop™ completed by US FDA · Findings presented, all of which Implantica considers to be minor · Decided to submit response to Module 1 together with Module 2 submission · NHS Trust University Hospital SouthamptonImplantica announces RefluxStop™ pivotal 4-year study results published in the prestigious journal Surgical Endoscopy
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces excellent long-term safety and clinical 4-year outcomes with the RefluxStop device (in the prospective multi-center CE study), which have recently been published in the prestigious journal, Surgical Endoscopy, an official journal of SAGES (American Gastrointestinal and Endoscopic Surgeons) and EAES (European Association For Endoscopic Surgery), entitled “Treating acid reflux withImplantica announces another landmark real-world RefluxStop™ study demonstrating excellent outcomes published in a prestigious top-tier journal
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces another key milestone with an independent study demonstrating robust safety and significant improvement in GERD symptoms after the RefluxStop™ procedure published in Swiss Medical Weekly (https://smw.ch/index.php/smw/article/view/3365/5988), a prestigious top-tier journal. The leading GERD researchers at Hirslanden Klinik Beau-Site Hospital in Bern, Switzerland, conducted an inde
Read more news
Frequently Asked Questions Regarding Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealt... Read More
